Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2023 Multiple Myeloma Highlights
27 June 2023 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in multiple myeloma from ASCO and EHA 2023
The Post-ASCO & EHA 2023 Multiple Myeloma Highlights was supported by Bristol Myers Squibb, Genentech and Legend Biotech. Supporters have no influence over the production of content.
Session 1: NDMM and RRMM
MASTER: Quad induction therapy, ASCT and MRD-modulated consolidation
Luciano Costa UAB School of Medicine, Birmingham, AL, United States
KPd for treating high-risk myeloma
Ajay Nooka Winship Cancer Institute of Emory University, Atlanta, GA, United States
KRd + elotuzumab vs KRd alone for newly diagnosed myeloma
Hermann Einsele Würzburg University Hospital, Würzburg, Germany
Selinexor in multiple myeloma
Maria Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
SUCCESSOR-2: MeziKd vs Kd in RRMM
Monique Hartley-Brown Dana-Farber Cancer Institute, Boston, MA, United States
Panel discussion
Session 2: CAR T-cell therapies
CARTITUDE-1: cilta-cel in heavily pretreated patients with RRMM
Saad Usmani Memorial Sloan Kettering Cancer Center, New York, NY, United States
KarMMa-3: ide-cel vs TCE RRMM
Krina Patel The University of Texas MD Anderson Cancer Center, Houston, TX, United States
PHE885 for treating R/R multiple myeloma
Adam Sperling Dana-Farber Cancer Institute, Boston, MA, United States
CARTITUDE-4: cilta-cel vs PVd OR DPd in LEN-refractory myeloma
Hermann Einsele Würzburg University Hospital, Würzburg, Germany
Panel discussion
Session 3: BCMA- & GPRC5D-targeted antibodies
DREAMM-3: Belantamab vs Pom-dex in RRMM
Meletios Dimopoulos University of Athens School of Medicine, Athens, Greece
Elranatamab in RRMM with prior BCMA-targeted therapy treatment
Ajay Nooka Winship Cancer Institute of Emory University, Atlanta, GA, United States
MagnetisMM-3: Elranatamab for RRMM (extended follow-up)
Mohamad Mohty Saint-Antoine Hospital, France
LINKER-MM1: Linvoseltamab in RRMM
Joshua Richter Mount Sinai Medical Center, NY, United States
BMS-986393 for relapsed/refractory multiple myeloma
Susan Bal University of Alabama, Birmingham, AL, United States
TRiMM-2: TAL + DARA for relapsed/refractory multiple myeloma
Paula Rodríguez-Otero University of Navarra, Navarra, Spain
Panel discussion
Session 4: I-O Combinations & novel therapies/early-stage trials
RedirecTT-1: teclistamab + talquetamab for RRMM
Maria Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
MAJESTEC-2: TEC + NIRO for RRMM
Jeffrey Matous Colorado Blood Cancer Institute, Denver, CO, United States
Tasquinimod alone and in combination with IRd for RRMM
Dan Vogl University of Pennsylvania, Philadelphia, PA, United States
Panel discussion
The Post-ASCO & EHA 2023 Myeloma Highlights webinar has been supported by:
